Search

Phenylalpha

Phenylalpha

phenylephrine

Manufacturer:

Laboratoire Aguettant

Distributor:

HK Medical Supplies

Marketer:

Aguettant
Concise Prescribing Info
Contents
Phenylephrine HCl
Indications/Uses
Hypotension during spinal, epidural or general anesth.
Click to view Phenylalpha detailed prescribing information
Dosage/Direction for Use
Adult IV bolus 50-100 mcg, repeat until desired effect is attained. Max bolus dose: 100 mcg. Continuous infusion 25-50 mcg/min, increase or decrease dose to maintain systolic BP close to normal value.
Click to view Phenylalpha detailed prescribing information
Overdosage
View Phenylalpha overdosage for action to be taken in the event of an overdose.
Contraindications
Hypersensitivity. Combination w/ non-selective MAOIs (or w/in 2 wk of their w/drawal). Patients w/ severe HTN or peripheral vascular disease; severe hyperthyroidism.
Click to view Phenylalpha detailed prescribing information
Special Precautions
Monitor arterial BP during treatment. Closely monitor vital organ functions & consider dose reduction when systemic BP is near the lower end of target range in patients w/ reduced cardiac output or coronary vascular disease. May cause deterioration in heart failure as a consequence of induced vasoconstriction in patients w/ serious heart failure or cardiogenic shock. Avoid extravasation; may cause tissue necrosis. Patients w/ DM; arterial HTN; uncontrolled hyperthyroidism; CHD & chronic heart conditions; non-severe peripheral vascular insufficiency; bradycardia; partial heart block; tachycardia; arrhythmias; angina pectoris; aneurysma; closed angle glaucoma; arteriosclerosis; impaired cerebral or coronary circulation; patients on controlled Na diet. Patients w/ renal or hepatic impairment. Pregnancy & lactation. May potentially cause fetal hypoxia & bradycardia if administered in late pregnancy or labour. Elderly. Childn.
Click to view Phenylalpha detailed prescribing information
Adverse Reactions
Bradycardia, hypertensive episodes, nausea & vomiting.
Click to view Phenylalpha detailed prescribing information
Drug Interactions
Paroxysmal HTN & hyperthermia w/ non-selective MAOI (eg, iproniazid, nialamide). Risk of vasoconstriction &/or hypertensive crisis w/ dopaminergic ergot alkaloids (bromocriptine, cabergoline, lisuride, pergolide); vasoconstrictor ergot alkaloids (dihydroergotamine, ergotamine, methylergometrine, methylsergide); selective type A MAOIs (moclobemide, toloxatone); linezolid. Paroxysmal HTN w/ possibility of arrhythmias w/ TCAs (eg, imipramine); noradrenergic-serotoninergic antidepressants (minalcipram, venlafaxine); sibutramine. Substantial BP increase w/ guanethidine & related products. Increased risk of arrhythmias w/ cardiac glycosides, quinidine. Risk of perioperative hypertensive crisis & arrhythmia w/ halogenated volatile anaesth (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane). Potentiated effect of presso-active sympathomimetic amines w/ oxytocic agents; severe persistent HTN & strokes can occur during post-partum period.
Click to view Phenylalpha detailed prescribing information
Caution For Usage
For caution against possible variation of physical aspect of medicine... Click to view Phenylalpha detailed prescribing information
Storage
View Phenylalpha storage conditions for details to ensure optimal shelf-life.
Description
View Phenylalpha description for details of the chemical structure and excipients (inactive components).
Action
View Phenylalpha mechanism of action for pharmacodynamics and pharmacokinetics details.
MIMS Class
Vasoconstrictors
ATC Classification
C01CA06 - phenylephrine ; Belongs to the class of adrenergic and dopaminergic cardiac stimulants excluding glycosides. Used in the treatment of hypotension.
Presentation/Packing
Form
Phenylalpha soln for inj 500 mcg/10 mL
Packing/Price
10 mL x 10 × 1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in